This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe

£200 Savings Ends In:

  • 00
  • 00
  • 00
  • 00
4 - 6 June, 2024
Excel London Platinum Suite

Niccolo Pengo, PhD
Chief Scientific Officer at Mabylon AG


Niccolo Pengo, after obtaining a PhD at San Raffaele University in Milan on B-cell immunology and investigating regulation of cellular degradative pathways at University College London (Pengo et al. Nat Immunol 2013, Pengo et al. Nat Comm 2017), continued his research in industry working on developing novel antibody therapeutics, first at UCB pharma in the UK, and then as Chief Scientific Officer of Mabylon, in Switzerland, a company dedicated to the discovery of novel human derived antibody therapeutics in immunology and neurodegeneration.

Agenda Sessions

  • Unlocking the Potential of Human-derived Antibodies